Published in Vaccine Weekly, July 8th, 1996
The highlight of the XI International Conference on AIDS, to be held July 7-12, 1996, in Vancouver, Canada, will be the presentation of clinical trial results showing that the most potent of the new HIV protease inhibitors - when combined with zidovudine (AZT) and lamivudine (3TC) - can control HIV infection.
Tantalizing data from small but growing numbers of subjects suggest that as long as people with HIV infection can continue taking the three-drug combination, they can remain free of AIDS symptoms.
But for the 80 percent of people with HIV...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly